Sona Nanotech, Inc. · CSE:SONA
Sona Nanotech — Investor Presentation (May 2025)
26 slides from Sona Nanotech's investor presentation, May 2025
Slide 1: A Novel and Non-toxic Immunotherapy Device
A Novel and Non-toxic Immunotherapy Device Priming the Immune System to Enhance Immunotherapy Response Rates Ma y 20 25 sonanano.com CSE: SONA | OTCQB: SNANF
Slide 2: Forward Looking Statement
Forward Looking Statement This presentation contains forward-looking information under Actual results may differ materially from those set forth in applicable securities law. All information that addresses this presentation due to risks and uncertainties affecting Sona activities or developments tha
Slide 3: Investment Highlights
Investment ➢ Gentle but powerful therapy – elegant and strong immune system Highlights activator • Heating tumors from the inside, out to elicit neo-antigens that engage the immune system and enhance immunotherapy drug response rates ➢ Uniquely biocompatible, patented and vetted nanotechnology platf
Slide 4: Immunotherapy Checkpoint Inhibitors Release The Brakes For The Immune System
Immunotherapy Checkpoint Inhibitors Release The Brakes For The Immune Immunotherapy has provided a ‘step change’ in cancer treatment System To More Readily Recognize and Attack Cancer Immunotherapy treatments harness the immune system to fight cancer on its own However, immunotherapy still has: ➢Lim
Slide 5: Pembrolizumab's Five-Year Overall Survival And Average Response Rates Were Just 34% and 21%
For Instance, Pembrolizumab’s Five-Year Overall Survival And Average Response Rates Were Shown To Be Just 34%(1) and 21%(2), Respectively Five Year Overall Survival Rates Immunotherapy Response Rate in Study of 1678 Patients by Cancer Type 100% 80% 60% 40% Average response rate of 21% 20% 0% Endomet
Slide 6: Immunotherapy Response Rates Are Low Because Tumor Antigens Are Too Weak
Immunotherapy Response Rates Are Low Because Tumor Antigens Presented Are Too Weak To Elicit An Immune Response Sources of Immunotherapy Resistance 1. Weak tumor antigen expression More of a good thing isn’t necessarily better: 2. Upregulation of immune-checkpoint molecules Addressing a weak antigen
Slide 7: Sona's Patented Gold Nanorods Heat Tumors Gently From The Inside
Sona’s Patented Gold Nanorods Heat Tumors Gently From The Inside, Causing Selective Apoptotic Cell Death* Which Reveals Neoantigens Sona’s Gold Nanorod’s (“GNR”) Advantages Functional: • Optimal nanoparticle for thermal conversion *Apoptotic Cell Death: • Can be ‘tuned’ to react to set wavelengths W
Slide 8: Sona's THT Heats Tumors With Near-infrared-activated GNRs
Sona’s THT Heats Tumors With Near-infrared-activated GNRs Turning Immunogenetically ‘Cold’ Tumors*, ‘Hot’ *Cold Tumors: Describes a tumor that is not likely to trigger a strong immune response. Cold tumors tend to be surrounded by cells that are able to suppress the immune response and keep T cells
Slide 9: Recent Study Demonstrates THT's Ability To Shrink Tumors
Recent Study Demonstrates Sona’s THT’s Ability To Shrink Tumors, Impact Score of 5.7 – top 10 of Immunology Journals Peer- Engage The Immune System And reviewed Enable Immunotherapy Study Recent Preclinical Study Shows THT’s Strong Efficacy in Melanoma and Triple Negative Breast Cancer, With Pronoun
Slide 10: Sona's Studies Examined
Sona’s Studies Examined The Impact Of Causing Peer- reviewed Hyperthermic Heat In Study Tumors With, And Protocol Without Immunotherapy Sona used three different treatment groups in its peer- reviewed study: 1. Control 2. THT alone 3. THT + immunotherapy (IL-2) 4. THT + immunotherapy (PD-1) Source:
Slide 11: Sona's THT Involves Two Injections Of GNRs Followed By Laser Energy
Sona’s THT Involves Two Injections Of GNRs Followed By ~5 Minutes Of Sona’s Near-infrared Laser Energy Which GNRs Convert To Heat Maintaining ‘hyperthermic’ heat (42-48C) destroys cancer cells, which have a lower tolerance to heat, while not harming healthy cells The laser energy passes harmlessly t
Slide 12: THT's Ability To Make Immunotherapies Work In Colorectal Cold Tumors
Sona’s Studies Demonstrated THT’s Ability To Make Immunotherapies Work In Colorectal ‘Cold’ Tumors…. New Data Tumor Volume - Colorectal Control Tumor Volume (mm3) 1000 THT PD1 THT+PD-1 (N=16) 500 Immunotherapy without THT 0 Immunotherapy with THT Laser PD-1 PD-1 PD-1 PD-1 5 25 Day Sona’s THT enabled
Slide 13: ...And Breast Cancer Cold Tumors
…And Breast Cancer ‘Cold’ Tumors New Data Tumor Volume - Breast 400 Tumor Volume (mm3) Control 300 IL2 (N=13) THT (N=15) 200 PD1 (N=2) THT+IL2 (N=12) 100 THT+PD1 (N=4) 0 Two different types of immunotherapy Laser GNR IL2/PD1 IL2/PD1 IL2/PD1 with THT Sona’s THT enabled tumor near elimination (N=2) wi
Slide 14: THT With Immunotherapy Prevented Growth In Distant, Untreated Tumors
Most Remarkably, THT With Immunotherapy Prevented Growth In Distant, Untreated Tumors In The Melanoma Model B16 - Melanoma THT Showed A Vaccine-like Effect In mice with one tumor treated with THT and IL-2, an abscopal effect was (single treatment) seen whereby distant, untreated Creates an tumors sh
Slide 15: Gene Expression Analysis Shows THT Alone Stimulates Innate Immune System
Gene Expression Analysis Provides Strong Evidence That THT Alone Causes Innate Immune System Stimulation 4T1 – Breast Cancer B16 - Melanoma Ccl7 Ccl7 Cxcl10 Cxcl10 Cxcl9 Cxcl9 Relative Gene Expression (ΔΔCt) Relative Gene Expression (ΔΔCt) IFNa1 IFNa1 IFNa4 IFNa4 20 IL12 IL12 6 IL18 15 IL18 IL1a IL1
Slide 16: Preclinical Studies Have Established Efficacy, Safety And Potential Applicability
Preclinical Studies Have Established Efficacy, Safety And Potential Applicability To Three Solid Cancer Types, So Far Conclusions From Sona’s Preclinical THT Efficacy And Safety Studies 1. When immunotherapies haven’t worked, THT has made it work 2. THT causes apoptotic cancer cell death, resulting
Slide 17: First-in-human, Early Feasibility Study Start Targeted For Q2
First-in-human, Early Feasibility Study Start Targeted For Q2 Early Feasibility Study Objectives Primary: Evaluate the safety of THT treatment in patients with late-stage metastatic melanoma who have failed/partially responded to current standard of care melanoma immunotherapy. Secondary: Evaluate t
Slide 18: Sona's THT Therapy is Proprietary And Benefits From IP Protection
Sona’s THT Therapy is Proprietary And Benefits From IP Protection Sona’s Four Sources of IP Advantage Patents: THT + drug combination: • Method for Manufacture of Biocompatible Gold Nanorods • Full patent filed and now pending. It is a • Issued: USA, Canada and South Korea. Pending: PCT, EU. combina
Slide 19: Sona Is Leveraging Its Biocompatible GNR Platform To Develop Further Applications
Sona Is Leveraging On Its Uniquely Biocompatible GNR Platform Technology To Develop Further Applications Sona’s Product Pipeline – By Stage Of Development Discovery and Pre-clinical Studies Early Feasibility Pilot Study Pivotal Study Concept Design (~10 patients) (15-45 patients) (100’s of patients)
Slide 20: Sona's Product Pipeline - Milestones
Sona Is Investing In Building On Its Uniquely Biocompatible GNR Platform Technology Sona’s Product Pipeline - Milestones 2025 2026 Program Q2 Q3 Q4 H1 H2 Biocompatibility EFS First-in- EFS Initial Pilot Study Pilot Study Initial THT Therapy Feasibility Study Results human Study First Dosing (1) Read
Slide 21: A Team That Hits Above The Company's Market Capitalization Weight
A Team That Hits Above The Company’s Market Capitalization Weight Board Mark Lievonen Walter Strapps PhD Neil Fraser Jim Megann Chairman Director Director Wayne Myles, KC Director o 25 years of experience in Director o Led vaccine maker Sanofi- o CEO of Khosla Ventures o Led Medtronic Canada for o E
Slide 22: Capitalization Table
Capitalization Table As of March 7, 2025 Market Capitalization Ownership Share Price C$0.30 Board and Market Cap. C$34M 16% Management 52 Week High/Low $0.56/$0.235 Capital Structure Issued & Outstanding 112.5M Options 5.9M Warrants 3.0M Public 84% 22
Slide 23: Thank you
BIOCOMPATIBLE GNR GOLD NANOROD TECHNOLOGY Thank you David Regan david@sonanano.com CEO Sona Nanotech Inc. +1 902 448 1416 sonanano.com 23 CSE: SONA | OTCQB: SNANF
Slide 24: Appendix: Biomarker data indicating impact and longevity of immune system modulation
Appendix Biomarker data indicating impact and longevity of immune system modulation 24
Slide 25: GNR-Induced Hyperthermia Upregulates Innate Immune Cells in 4T1 and B16 Tumors
GNR-Induced Hyperthermia Upregulates Innate Immune Cells in 4T1 and B16 Tumors NK cells Dendritic cell count Macrophage count M1 Count 60000 ✱✱ ✱✱ 15000 80000 60000 4T1 – Breast Cancer ✱ Cell count/10^6 cells Cell count/10^6 cells Cell count/10^6 cells Cell count/10^6 cells 60000 10000 40000 40000 4
Slide 26: Enhanced infiltration of CD8+ T cells into Tumors Treated with Combination Therapy
Enhanced infiltration of CD8+ T cells into Tumors Treated with Combination Therapy CD8+ PD1+ %CD8 % of CD8+ that are CM 15000 ✱ ✱ ✱✱ 4T1 – Breast Cancer Cell count/10^6 cells 100 ✱ 60 10000 80 PD-1+ %CD8 PD-1+ %CD8 60 40 5000 40 20 20 0 0 0 PBS IL2 GNR Combo PBS IL2 GNR Combo PBS IL2 GNR Combo CD8+